Resolving the micro-heterogeneity and structural integrity of monoclonal antibodies by hybrid mass spectrometric approaches

ABSTRACT For therapeutic monoclonal antibodies (mAbs), detailed analysis of the structural integrity and heterogeneity, which results from multiple types of post-translational modifications (PTMs), is relevant to various processes, including product characterization, storage stability and quality control. Despite the recent rapid development of new bioanalytical techniques, it is still challenging to completely characterize the proteoform profile of a mAb. As a nearly indispensable tool in mAb analysis, mass spectrometry (MS) provides unique structural information at multiple levels. Here, we tested a hybrid strategy for the comprehensive characterization of micro-heterogeneity by integrating 2 state-of-the-art MS-based approaches, high-resolution native MS and targeted glycan profiling, to perform complementary analysis at the intact protein level and released glycan level, respectively. We compared the performance of these methods using samples of engineered half-body IgG4s and a panel of mAbs approved for human use. The glycosylation characterization data derived from these approaches were found to be mutually consistent in composition profiling, and complementary in identification and relative-quantitation of low-abundant uncommon glycoforms. In addition, multiple other sources of micro-heterogeneity, such as glycation, lack of glycosylation, and loss of light chains, could be detected by this approach, and the contribution of multiple types of modifications to the overall micro-heterogeneity could be assessed using our superposition algorithm. Our data demonstrate that the hybrid strategy allows reliable and thorough characterization of mAbs, revealing product characteristics that would easily be missed if only a single approach were used.

[1]  A. Heck,et al.  Hybrid mass spectrometry approaches in glycoprotein analysis and their usage in scoring biosimilarity , 2016, Nature Communications.

[2]  Kornél Viski,et al.  Parallel development of chromatographic and mass-spectrometric methods for quantitative analysis of glycation on an IgG1 monoclonal antibody. , 2016, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[3]  Kurt Brorson,et al.  N-Glycosylation Design and Control of Therapeutic Monoclonal Antibodies. , 2016, Trends in biotechnology.

[4]  Yi Wang,et al.  Simultaneous monitoring of oxidation, deamidation, isomerization, and glycosylation of monoclonal antibodies by liquid chromatography-mass spectrometry method with ultrafast tryptic digestion , 2016, mAbs.

[5]  C. Lebrilla,et al.  Quantitation of Site-Specific Glycosylation in Manufactured Recombinant Monoclonal Antibody Drugs. , 2016, Analytical chemistry.

[6]  S. Mohammed,et al.  Optimal Synthetic Glycosylation of a Therapeutic Antibody , 2016, Angewandte Chemie.

[7]  C. Lebrilla,et al.  A Method for In-Depth Structural Annotation of Human Serum Glycans That Yields Biological Variations. , 2015, Analytical chemistry.

[8]  E. M. Cook,et al.  Human IgG is produced in a pro-form that requires clipping of C-terminal lysines for maximal complement activation , 2015, mAbs.

[9]  Ramsey A Saleem,et al.  A chemical and computational approach to comprehensive glycation characterization on antibodies , 2015, mAbs.

[10]  J Michael Ramsey,et al.  Integrated microfluidic capillary electrophoresis-electrospray ionization devices with online MS detection for the separation and characterization of intact monoclonal antibody variants. , 2015, Analytical chemistry.

[11]  K. Brorson,et al.  Therapeutic monoclonal antibodies and consistent ends: terminal heterogeneity, detection, and impact on quality. , 2014, Current opinion in biotechnology.

[12]  C. Lebrilla,et al.  In-Depth Method for the Characterization of Glycosylation in Manufactured Recombinant Monoclonal Antibody Drugs , 2014, Analytical chemistry.

[13]  A. Heck,et al.  Detailed mass analysis of structural heterogeneity in monoclonal antibodies using native mass spectrometry , 2014, Nature Protocols.

[14]  Weidong Cui,et al.  Mass spectrometry for the biophysical characterization of therapeutic monoclonal antibodies , 2014, FEBS letters.

[15]  P. Parren,et al.  In-depth qualitative and quantitative analysis of composite glycosylation profiles and other micro-heterogeneity on intact monoclonal antibodies by high-resolution native mass spectrometry using a modified Orbitrap , 2013, mAbs.

[16]  D. Suckau,et al.  Correct primary structure assessment and extensive glyco-profiling of cetuximab by a combination of intact, middle-up, middle-down and bottom-up ESI and MALDI mass spectrometry techniques , 2013, mAbs.

[17]  P. Parren,et al.  Mutation of Y407 in the CH3 domain dramatically alters glycosylation and structure of human IgG , 2013, mAbs.

[18]  A. Deelder,et al.  Glycoproteomic Analysis of Antibodies , 2013, Molecular & Cellular Proteomics.

[19]  Alain Van Dorsselaer,et al.  Characterization of therapeutic antibodies and related products. , 2013, Analytical chemistry.

[20]  Albert J R Heck,et al.  High-sensitivity Orbitrap mass analysis of intact macromolecular assemblies , 2012, Nature Methods.

[21]  John R. Engen,et al.  Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars , 2012, Nature Reviews Drug Discovery.

[22]  Alain Van Dorsselaer,et al.  Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry. , 2012, Analytical chemistry.

[23]  R. Bayer,et al.  The impact of glycosylation on monoclonal antibody conformation and stability , 2011, mAbs.

[24]  Kim Vo,et al.  Isolation and characterization of IgG1 with asymmetrical Fc glycosylation. , 2011, Glycobiology.

[25]  Armin Ruf,et al.  Unique carbohydrate–carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose , 2011, Proceedings of the National Academy of Sciences.

[26]  Feng Li,et al.  Cell culture processes for monoclonal antibody production , 2010, mAbs.

[27]  Christian Bailly,et al.  Strategies and challenges for the next generation of therapeutic antibodies , 2010, Nature Reviews Immunology.

[28]  Damian Houde,et al.  Post-translational Modifications Differentially Affect IgG1 Conformation and Receptor Binding* , 2010, Molecular & Cellular Proteomics.

[29]  D. Hambly,et al.  The effect of sucrose hydrolysis on the stability of protein therapeutics during accelerated formulation studies. , 2009, Journal of pharmaceutical sciences.

[30]  P. Bondarenko,et al.  Mass measurement and top-down HPLC/MS analysis of intact monoclonal antibodies on a hybrid linear quadrupole ion trap-orbitrap mass spectrometer , 2009, Journal of the American Society for Mass Spectrometry.

[31]  André M Deelder,et al.  IgG glycosylation analysis , 2009, Proteomics.

[32]  R. Jefferis.  Glycosylation of Recombinant Antibody Therapeutics , 2008, Biotechnology progress.

[33]  Difei Qiu,et al.  C‐terminal lysine variants in fully human monoclonal antibodies: Investigation of test methods and possible causes , 2008, Biotechnology and bioengineering.

[34]  T. Raju,et al.  Terminal sugars of Fc glycans influence antibody effector functions of IgGs. , 2008, Current opinion in immunology.

[35]  Andreas Rizzi,et al.  Analysis of lysine clipping of a humanized Lewis-Y specific IgG antibody and its relation to Fc-mediated effector function. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[36]  Pauline M Rudd,et al.  The impact of glycosylation on the biological function and structure of human immunoglobulins. , 2007, Annual review of immunology.

[37]  Gary Walsh,et al.  Post-translational modifications in the context of therapeutic proteins , 2006, Nature Biotechnology.

[38]  T. Niwa.  Mass spectrometry for the study of protein glycation in disease. , 2006, Mass spectrometry reviews.

[39]  E. Williams,et al.  Origin of asymmetric charge partitioning in the dissociation of gas-phase protein homodimers. , 2003, Journal of the American Chemical Society.

[40]  H. McNulty,et al.  Demonstration of glycated insulin in human diabetic plasma and decreased biological activity assessed by euglycemic-hyperinsulinemic clamp technique in humans. , 2003, Diabetes.

[41]  K. Shitara,et al.  The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity* , 2003, The Journal of Biological Chemistry.

[42]  L. Presta,et al.  Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity* , 2002, The Journal of Biological Chemistry.

[43]  A. Lapolla,et al.  Non-enzymatic glycation of IgG: an in vivo study. , 2002, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[44]  R. Spiro.  Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds. , 2002, Glycobiology.

[45]  I. Shimada,et al.  Pairing of oligosaccharides in the Fc region of immunoglobulin G , 2000, FEBS letters.

[46]  J. Mora,et al.  Electrospray ionization of large multiply charged species proceeds via Dole’s charged residue mechanism , 2000 .

[47]  A K Patel,et al.  The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. , 1995, Molecular immunology.

[48]  U. Marx,et al.  Influence of cell‐ and media‐derived factors on the integrity of a human monoclonal antibody after secretion into serum‐free cell culture supernatants , 1995, Biotechnology and bioengineering.

[49]  S. Muyldermans,et al.  Naturally occurring antibodies devoid of light chains , 1993, Nature.

[50]  J. Young,et al.  Effect of Culture Conditions on IgM Antibody Structure, Pharmacokinetics and Activity , 1993, Bio/Technology.

[51]  B. Shilton,et al.  Sites of glycation of human and horse liver alcohol dehydrogenase in vivo. , 1991, The Journal of biological chemistry.

[52]  J. Kearney,et al.  Posttranslational association of immunoglobulin heavy chain binding protein with nascent heavy chains in nonsecreting and secreting hybridomas , 1986, The Journal of cell biology.

[53]  R. Garlick,et al.  The principal site of nonenzymatic glycosylation of human serum albumin in vivo. , 1983, The Journal of biological chemistry.

[54]  L. Hood,et al.  gamma Heavy chain disease in man: cDNA sequence supports partial gene deletion model. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[55]  Wei Wang,et al.  Antibody structure, instability, and formulation. , 2007, Journal of pharmaceutical sciences.

[56]  C. Enke,et al.  Practical implications of some recent studies in electrospray ionization fundamentals. , 2001, Mass spectrometry reviews.

[57]  A. Lapolla,et al.  The in vivo glyco-oxidation of alpha- and beta-globins investigated by matrix-assisted laser desorption/ionization mass spectrometry. , 1996, Rapid communications in mass spectrometry : RCM.